Laurus Labs has signed Share Purchase agreements with one of the Promoters and non-executive director and his family members and also with few employees/ex-employee shareholders of Laurus Bio for purchase of 37,641 equity shares through secondary purchase. With this acquisition, the shareholding of the Company in Laurus Bio will become 87.58% on fully diluted basis (including outstanding share warrants and ESOP Pool).
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
